A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Mylan, the profiteering, tax-dodging drug company currently taking immense heat for jacking up the price of its Epipen by 500%, announced Thursday that it will help more patients cover their ...

Mylan, which showered itself in infamy by jacking up the price of its EpiPen, a potentially life-saving epinephrine injector, by 500% over less than a decade, announced Friday that it is finally ...

Mylan, which offers 635 products in the U.S., has spent $1 billion to improve the EpiPen by increasing its availability through patient-assistance programs that it has recently bolstered.

Mylan's generic version will hit shelves within several weeks at a list price of $300 for a two-pack carton in dosages of either 0.15 milligrams or 0.30 mg, the company said.

Tax experts have said that Mylan is actually paying much less in taxes. Excluding taxes, EpiPen’s profits per two-pack are close to $170. This left lawmakers shaking their heads. “We didn’t ...